Hemodialysis as a Risk Factor for Ceftriaxone‐Associated Pseudolithiasis in Adults

Ceftriaxone‐associated biliary pseudolithiasis is common among children; however, there are only a few reports of pseudolithiasis in adult patients on HD. This retrospective cohort study included 278 adult patients on ceftriaxone therapy from 1 February 2016 to 1 September 2018. Pseudolithiasis was...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic apheresis and dialysis 2020-08, Vol.24 (4), p.393-399
Main Authors: Ubukata, Masamitsu, Ohsawa, Isao, Suzuki, Hiroki, Asao, Rin, Nakamura, Yuya, Nishida, Hirofumi, Nakamura, Masayuki, Nitta, Kosaku, Goto, Yoshikazu, Gotoh, Hiromichi
Format: Article
Language:English
Subjects:
Adverse effect
Aged
Ceftriaxone
Ceftriaxone - adverse effects
Cholelithiasis - chemically induced
Cohort Studies
End‐stage renal disease
Female
Hemodialysis
Humans
Male
Pseudolithiasis
Renal Dialysis - adverse effects
Retrospective Studies
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftriaxone‐associated biliary pseudolithiasis is common among children; however, there are only a few reports of pseudolithiasis in adult patients on HD. This retrospective cohort study included 278 adult patients on ceftriaxone therapy from 1 February 2016 to 1 September 2018. Pseudolithiasis was defined as a new development of sludge or stones in the gallbladder within 60 days of ceftriaxone therapy. After excluding patients with preexisting gallstones and a history of cholecystectomy, 113 patients on maintenance HD, and another 98 patients were enrolled as the HD and control group, respectively. Thirteen patients developed pseudolithiasis. Its incidence was significantly higher in the HD group than that in the control group. Multivariate logistic regression analyses showed that development of pseudolithiasis was significantly associated with HD and ceftriaxone dose. Therefore, HD in patients receiving ceftriaxone therapy appears to be associated with a risk of pseudolithiasis. These findings highlight the need for careful follow‐up.
ISSN:1744-9979
1744-9987
DOI:10.1111/1744-9987.13445